Sinovac up 6% premarket

Shares of Sinovac Biotech (SVA) are poised for a modest pop this morning in response to its earnings release.

Cash and equivalents totaled $107.2M at year end.

Consensus estimates for 2014 and 2015 are a loss of $0.05/share on revenues of $81M and earnings of $0.15/share on revenues of $108M, respectively.

25 mutual funds have positions, up from 24 a year earlier.

From other sites
Comments (1)
  • 11146471
    , contributor
    Comments (1381) | Send Message
    Tremendous financials.


    Even after today's run is at very low/cheap valuation.
    20 Mar 2014, 12:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs